Compare AngloGold Ashanti Limited (AU) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs BioNano Genomics Inc — how do they compare? AngloGold Ashanti Limited trades at $97.76 (market cap $49.28B), while BioNano Genomics Inc trades at $1.19 (market cap $13.66M). The key difference: AngloGold Ashanti Limited is far larger — about 3607.6× BioNano Genomics Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AU | BNGO | |
|---|---|---|
Market Cap | $49.28B | $13.66M |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $4.92 |
52-Week Low | $52.15 | $1.06 |
Enterprise Value | $48.29B | $16.26M |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $98.20, up 0.98% today, near its 52-week high. The stock shows strong fundamental momentum with revenue surging to $9.89B in 2025 and net income reaching $2.64B. Analysts maintain a bullish consensus with a $120.33 price target, supported by robust cash flow and a $2B buyback program. Technical indicators are mixed, with moving averages bullish but RSI levels suggesting overbought conditions. Recent news highlights operational strength and institutional accumulation.
Outlook remains positive driven by gold price strength and production growth, but risks include commodity volatility and operational execution. The stock offers value with a P/E of 13.06 and high profitability margins, though overbought technicals may prompt near-term consolidation. Investor sentiment is favorable, but macroeconomic factors could impact performance.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
